Cite
HARVARD Citation
KOBAYASHI, M. et al. (2018). Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3‐Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?. LUTS. 10 (2), pp. 158-166. [Online].